Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.04
-0.5300-1.92%
Post-market: 27.03-0.0100-0.04%19:59 EDT
Volume:29.12M
Turnover:794.31M
Market Cap:153.74B
PE:19.88
High:27.77
Open:27.73
Low:27.02
Close:27.57
52wk High:27.94
52wk Low:20.92
Shares:5.69B
Float Shares:5.68B
Volume Ratio:0.69
T/O Rate:0.51%
Dividend:1.72
Dividend Rate:6.36%
EPS(TTM):1.36
EPS(LYR):1.36
ROE:8.89%
ROA:5.68%
PB:1.78
PE(LYR):19.82

Loading ...

Pfizer Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Mar 03

US asks smaller drugmakers to discuss lowering prices for Medicaid

Reuters
·
Mar 03

Pfizer Raised to Buy From Hold by Argus Research

Dow Jones
·
Mar 03

Pfizer CEO flags issues with FDA's vaccine leadership

Reuters
·
Mar 03

Pfizer CEO Says Co Will Be "in the Forefront of Testing the Most Aggressive Forms of Being Able to Maximize" the Obesity Portfolio -TD Cowen Conf

THOMSON REUTERS
·
Mar 02

Pfizer CEO Says Current Director of FDA's Cber "Is Not Following the Recommendations of His Staff" -TD Cowen Conf

THOMSON REUTERS
·
Mar 02

Pfizer CEO Says Co Expects Newly Launched Products to Continue to Grow Double Digit This Year -TD Cowen Conf

THOMSON REUTERS
·
Mar 02

Positive Report for Pfizer (PFE) from Argus Research

TIPRANKS
·
Mar 02

Pfizer : Argus Research Raises to Buy Rating

THOMSON REUTERS
·
Mar 02

Argus upgrades Pfizer to Buy, citing GLP-1 pipeline, oncology programs

TIPRANKS
·
Mar 02

Pfizer Ramps Up Obesity, mRNA Flu and Skin-Drug Bets

TIPRANKS
·
Feb 28

Pfizer’s New mCRC Standard Of Care And What It Means For Valuation

Simply Wall St.
·
Feb 28

NYSE Most Active Issues

Dow Jones
·
Feb 28

Pfizer Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Feb 28

Pfizer’s Tranquillo Vitiligo Trial Nears Key Data Phase, Setting Up a New Dermatology Catalyst for PFE

TIPRANKS
·
Feb 28

Merck, Pfizer Report Positive Results From Combined Bladder-Cancer Trial

Dow Jones
·
Feb 27

Pfizer, Astellas announce results from Phase 3 EV-304 trial for PADCEV

TIPRANKS
·
Feb 27

Pfizer reports PADCEV plus Keytruda halves recurrence or death risk in Phase 3 muscle-invasive bladder cancer trial

Reuters
·
Feb 27

Pfizer FY 2025 Paxlovid revenue USD 2.4 billion down 59%

Reuters
·
Feb 27

This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Benzinga_recent_news
·
Feb 26